The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Sirolimus for Kaposi's Sarcoma in Renal-Transplant Recipients
Open accessAbstract
BACKGROUND: Recipients of organ transplants are susceptible to Kaposi's sarcoma as a result of treatment with immunosuppressive drugs. Sirolimus (rapamycin), an immunosuppressive drug, may also have antitumor effects. METHODS: We stopped cyclosporine therapy in 15 kidney-transplant recipients who had biopsy-proven Kaposi's sarcoma and began sirolimus therapy. All patients underwent an excisional biopsy of the lesion and one biopsy of normal skin at the time of diagnosis. A second biopsy was performed at the site of a previous Kaposi's sarcoma lesion six months after sirolimus therapy was begun. We examined biopsy specimens for vascular endothelial growth factor (VEGF), Flk-1/KDR protein, and phosphorylated Akt and p70S6 kinase, two enzymes in the signaling pathway targeted by sirolimus. RESULTS: Three months after sirolimus therapy was begun, all cutaneous Kaposi's sarcoma lesions had disappeared in all patients. Remission was confirmed histologically in all patients six months after sirolimus therapy was begun. There were no acute episodes of rejection or changes in kidney-graft function. Levels of Flk-1/KDR and phosphorylated Akt and p70S6 kinase were increased in Kaposi's sarcoma cells. The expression of VEGF was increased in Kaposi's sarcoma cells and even more so in normal skin cells around the Kaposi's sarcoma lesions. CONCLUSIONS: Sirolimus inhibits the progression of dermal Kaposi's sarcoma in kidney-transplant recipients while providing effective immunosuppression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Identification of Herpesvirus-Like DNA Sequences in AIDS-Sssociated Kaposi's Sarcoma
Chang, Y., Cesarman, E., Pessin, M. S., Lee, F., Culpepper, J., Knowles, D. M., & Moore, P. S. (1994) · Science · doi:10.1126/science.7997879 · Cited by 5,654
Cantley, L. C., & Neel, B. G. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.8.4240 · Cited by 2,006
Gerber, H.-P., McMurtrey, A., Kowalski, J., Yan, M., Keyt, B. A., Dixit, V., & Ferrara, N. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.46.30336 · Cited by 1,981
Guba, M., von Breitenbuch, P., Steinbauer, M., Koehl, G., Flegel, S., Hornung, M., Bruns, C. J., Zuelke, C., Farkas, S., Anthuber, M., et al. (2002) · Nature Medicine · doi:10.1038/nm0202-128 · Cited by 1,739
Cyclosporine induces cancer progression by a cell-autonomous mechanism
Hojo, M., Morimoto, T., Maluccio, M., Asano, T., Morimoto, K., Lagman, M., Shimbo, T., & Suthanthiran, M. (1999) · Nature · doi:10.1038/17401 · Cited by 1,149
Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy
Wendel, H.-G., Stanchina, E. D., Fridman, J. S., Malina, A., Ray, S., Kogan, S., Cordon-Cardo, C., Pelletier, J., & Lowe, S. W. (2004) · Nature · doi:10.1038/nature02369 · Cited by 951
The translation factor eIF-4E promotes tumor formation and cooperates with c-Myc in lymphomagenesis
Ruggero, D., Montanaro, L., Ma, L., Xu, W., Londei, P., Cordon-Cardo, C., & Pandolfi, P. P. (2004) · Nature Medicine · doi:10.1038/nm1042 · Cited by 586
Masood, R., Cai, J., Zheng, T., Smith, D. L., Naidu, Y., & Gill, P. S. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.3.979 · Cited by 279
Conversion to sirolimus: a successful treatment for posttransplantation Kaposi???s sarcoma12
Campistol, J. M., Gutierrez-Dalmau, A., & Torregrosa, J. V. (2004) · Transplantation · doi:10.1097/01.tp.0000115344.18025.0b · Cited by 261
Rapamycin blocks tumor progression: unlinking immunosuppression from antitumor efficacy1
Luan, F. L., Hojo, M., Maluccio, M., Yamaji, K., & Suthanthiran, M. (2002) · Transplantation · doi:10.1097/00007890-200205270-00008 · Cited by 235
Cited by
Defining the role of mTOR in cancer
Guertin, D. A., & Sabatini, D. M. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.05.008 · Cited by 2,833
Targeting the phosphoinositide 3-kinase pathway in cancer
Liu, P., Cheng, H., Roberts, T. M., & Zhao, J. J. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2926 · Cited by 2,721
Special Issue: KDIGO Clinical Practice Guideline for the Care of Kidney Transplant Recipients
Eckardt, K.-U., Kasiske, B. L., & Zeier, M. G. (2009) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2009.02834.x · Cited by 1,499
G-protein-coupled receptors and cancer
Dorsam, R. T., & Gutkind, J. S. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2069 · Cited by 1,388
mTOR and cancer: insights into a complex relationship
Sabatini, D. M. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1974 · Cited by 1,322
Kaposi's sarcoma and its associated herpesvirus
Mesri, E. A., Cesarman, E., & Boshoff, C. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2888 · Cited by 880
Cesarman, E., Damania, B., Krown, S. E., Martin, J., Bower, M., & Whitby, D. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0060-9 · Cited by 697
Targeting the mTOR Signaling Network for Cancer Therapy
Meric-Bernstam, F., & Gonzalez-Angulo, A. M. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.0766 · Cited by 639
Malignancy after Transplantation
Buell, J. F., Gross, T. G., & Woodle, E. S. (2005) · Transplantation · doi:10.1097/01.tp.0000186382.81130.ba · Cited by 595
Outcomes of Kidney Transplantation in HIV-Infected Recipients
Stock, P. G., Barin, B., Murphy, B., Hanto, D., Diego, J. M., Light, J., Davis, C., Blumberg, E., Simon, D., Subramanian, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001197 · Cited by 531
Campistol, J. M., Eris, J., Oberbauer, R., Friend, P., Hutchison, B., Morales, J. M., Claesson, K., Stallone, G., Russ, G., Rostaing, L., et al. (2006) · Journal of the American Society of Nephrology · doi:10.1681/asn.2005090993 · Cited by 478
Self-citationPathological angiogenesis is induced by sustained Akt signaling and inhibited by rapamycin
Phung, T. L., Ziv, K., Dabydeen, D., Eyiah-Mensah, G., Riveros, M., Perruzzi, C., Sun, J., Monahan-Earley, R. A., Shiojima, I., Nagy, J. A., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.07.003 · Cited by 438
Immunosuppressive Therapy and Malignancy in Organ Transplant Recipients: A Systematic Review
Gutierrez-Dalmau, A., & Campistol, J. M. (2007) · Drugs · doi:10.2165/00003495-200767080-00006 · Cited by 408
KSHV and the pathogenesis of Kaposi sarcoma: listening to human biology and medicine
Ganem, D. (2010) · Journal of Clinical Investigation · doi:10.1172/jci40567 · Cited by 385
Shuda, M., Kwun, H. J., Feng, H., Chang, Y., & Moore, P. S. (2011) · Journal of Clinical Investigation · doi:10.1172/jci46323 · Cited by 374
Webster, A. C., Lee, V. W. S., Chapman, J. R., & Craig, J. C. (2006) · Transplantation · doi:10.1097/01.tp.0000219703.39149.85 · Cited by 335
Akt Signals through the Mammalian Target of Rapamycin Pathway to Regulate CNS Myelination
Narayanan, S. P., Flores, A. I., Wang, F., & Macklin, W. B. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.0232-09.2009 · Cited by 325
The PI3K/Akt/mTOR pathway in innate immune cells: emerging therapeutic applications
Weichhart, T., & Säemann, M. D. (2008) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2008.098459 · Cited by 323
Neuberger, J. M., Bechstein, W. O., Kuypers, D. R. J., Burra, P., Citterio, F., De Geest, S., Duvoux, C., Jardine, A. G., Kamar, N., Krämer, B. K., et al. (2017) · Transplantation · doi:10.1097/tp.0000000000001651 · Cited by 315
Molecular mechanisms of viral oncogenesis in humans
Krump, N. A., & You, J. (2018) · Nature Reviews Microbiology · doi:10.1038/s41579-018-0064-6 · Cited by 295
Wahl, P. R., Serra, A. L., Le Hir, M., Molle, K. D., Hall, M. N., & Wüthrich, R. P. (2006) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfi181 · Cited by 287
Dickinson, J. M., Fry, C. S., Drummond, M. J., Gundermann, D. M., Walker, D. K., Glynn, E. L., Timmerman, K. L., Dhanani, S., Volpi, E., & Rasmussen, B. B. (2011) · The Journal of Nutrition · doi:10.3945/jn.111.139485 · Cited by 282
Emerging therapeutic targets in endometrial cancer
Dedes, K. J., Wetterskog, D., Ashworth, A., Kaye, S. B., & Reis-Filho, J. S. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.216 · Cited by 270
Immunosuppressive Drugs and the Risk of Cancer after Organ Transplantation
Dantal, J., & Soulillou, J.-P. (2005) · New England Journal of Medicine · doi:10.1056/nejme058018 · Cited by 256
Baker, R. J., Mark, P. B., Patel, R. K., Stevens, K. K., & Palmer, N. (2017) · BMC Nephrology · doi:10.1186/s12882-017-0553-2 · Cited by 211
Roles of mTOR complexes in the kidney: implications for renal disease and transplantation
Fantus, D., Rogers, N. M., Grahammer, F., Huber, T. B., & Thomson, A. W. (2016) · Nature Reviews Nephrology · doi:10.1038/nrneph.2016.108 · Cited by 208
Bhutani, M., Polizzotto, M. N., Uldrick, T. S., & Yarchoan, R. (2015) · Seminars in Oncology · doi:10.1053/j.seminoncol.2014.12.027 · Cited by 155
Increased mTOR activation in idiopathic multicentric Castleman disease
Arenas, D. J., Floess, K., Kobrin, D., Pai, R.-A. L., Srkalovic, M. B., Tamakloe, M.-A., Rasheed, R., Ziglar, J., Khor, J., Parente, S. A. T., et al. (2020) · Blood · doi:10.1182/blood.2019002792 · Cited by 83
Sofroniadou, S., & Goldsmith, D. (2011) · Drug Safety · doi:10.2165/11585040-000000000-00000 · Cited by 60
Rapamycin-Induced Glucose Intolerance: Hunger or Starvation Diabetes
Blagosklonny, M. V. (2011) · Cell Cycle · doi:10.4161/cc.10.24.18595 · Cited by 59
Metadata
- Authors
- Stallone, G., Schena, A., Infante, B., Di Paolo, S., Loverre, A., Maggio, G., Ranieri, E., Gesualdo, L., Schena, F. P., & Grandaliano, G.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2005-03-31
- Volume
- 352
- Issue
- 13
- Pages
- 1317-1323
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2058562532
- Cited by
- 990
- References
- 18
- FWCI
- 35.33
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.